Clinical evaluation of the oral probiotic Streptococcus salivarius K12 in the prevention of recurrent pharyngitis and/or tonsillitis caused by Streptococcus pyogenes in adults

Expert Opinion on Biological Therapy

Volumn 13, Issue 3, 2013, Pages 339-343

  Di Pierro, Francesco ^a   Adami, Teresa ^b   Rapacioli, Giuliana ^c   Giardini, Nadia ^d   Streitberger, Christian ^d  

^a Velleja Research   (Italy)

^b Infective Diseases   (Italy)

^c AIOR   (Italy)

^d Merano Hospital   (Italy)

Author keywords

Bactoblis ; BLIS; Pharyngitis; Streptococcus salivarius K12; Tonsillitis

Indexed keywords

ANTIBIOTIC AGENT; BACTOBLIS; CHLORHEXIDINE; CORTICOSTEROID; HYALURONIC ACID; PROBIOTIC AGENT; UNCLASSIFIED DRUG;

ADULT; ADULT DISEASE; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BACTERIAL STRAIN; BEDTIME DOSAGE; CASE CONTROL STUDY; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; INFECTION PREVENTION; MALE; MEDICAL HISTORY; PHARYNGITIS; RECURRENT INFECTION; SELF REPORT; STREPTOCOCCAL PHARYNGITIS; STREPTOCOCCUS PYOGENES; STREPTOCOCCUS SALIVARIUS; TONSILLITIS; TREATMENT DURATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; FEMALE; HUMANS; MALE; MIDDLE AGED; PHARYNGITIS; PROBIOTICS; RECURRENCE; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS; STREPTOCOCCUS PYOGENES; TONSILLITIS; YOUNG ADULT;

EID: 84873915449     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2013.758711     Document Type: Article

References (21)

1. Sathyabama S, Vijayabharathi R, Bruntha Devi P, et al. Screening for probiotic properties of strains isolated from feces of various human groups. J Microbiol 2012;50:603-12
2. Tagg JR, Dierksen KP. Bacterial replacement therapy: adapting 'germ warfare' to infection prevention. Trends Biotechnol 2003;21:217-23
3. Tagg JR. Prevention of streptococcal pharyngitis by anti-Streptococcus pyogenes bacteriocin-like inhibitory substances (BLIS) produced by Streptococcus salivarius. Indian J Med Res 2004;119(Suppl):13-16
4. Jack RW, Tagg JR, RAY B. Bacteriocins of gram-positive bacteria. Microbiol Rev 1995;59:171-200
5. Sharma S, Verma KK. Skin and soft tissue infection. Indian J Pediatr 2001;68(Suppl 3):S46-50
6. Hyink O, Wescombe PA, Upton M, et al. Salivaricin A2 and the novel lantibiotic salivaricin B are encoded at adjacent loci on a 190-kilobase transmissible megaplasmid in the oral probiotic strain Streptococcus salivarius K12. Appl Environ Microbiol 2007;74:1107-13
7. Wescombe PA, Burton JP, Cadieux PA, et al. Megaplasmids encode differing combinations of lantibiotics in Streptococcus salivarius. Antonie van Leeuwenhoek 2006;90:269-80
8. Burton JP, Chilcott CN, Tagg JR. The rationale and potential for the reduction of oral malodour using Streptococcus salivarius probiotics. Oral Dis 2005;11(Suppl 1):29-31
9. Burton JP, Chilcott CN, Moore CJ, et al. A preliminary study of the effect of probiotic Streptococcus salivarius K12 on oral malodour parameters. J Appl Microbiol 2006;100:754-64
10. Power DA, Burton JP, Chilcott CN, et al. Preliminary investigations of the colonisation of upper respiratory tract tissues of infants using a paediatric formulation of the oral probiotic Streptococcus salivarius K12. Eur J Clin Microbiol Infect Dis 2008;27:1261-3
11. Horz HP, Meinelt A, Houben B, et al. Distribution and persistence of probiotic Streptococcus salivarius K12 in the human oral cavity as determined by real-time quantitative polymerase chain reaction. Oral Microbiol Immunol 2007;22:126-30
12. Burton JP, Wescombe PA, Moore CJ, et al. Safety assessment of the oral cavity probiotic Streptococcus salivarius K12. Appl Environ Microbiol 2006;72:3050-3
13. Burton JP, Cowley S, Simon RR, et al. Evaluation of safety and human tolerance of the oral probiotic Streptococcus salivarius K12: a randomized, placebo-controlled, double-blind study. Food Chem Toxicol 2011;49:2356-64
14. Tagg J, Wescombe P, Burton J. Oral streptococcal BLIS: Heterogeneity of the effector molecules and potential role in the prevention of streptococcal infections. Int Congress Series 2006;1289:347-50
15. Vandenbroucke JP. A shortcut method for calculating the 95 per cent confidence interval of the standardised mortality ratio. Am J Epidemol 1982;115:303
16. Tagg JR. A longitudinal study of Lancefield group A streptococcus acquisitions by a group of young Dunedin school children. NZ Med J 1990;103:429-31
17. Fantinato VC, Shimizu MT. Production of bacteriocin-like inhibitory substances (BLIS) by Streptococcus salivarius strains isolated from the tongue and throat of children with and without sore throat. Rev Microbiol 1999;30:332-4
18. Ragland N, Tagg JR. Applications of bacteriocin-like inhibitory substance (BLIS) typing in a longitudinal study of the oral carriage of beta-haemolytic streptococci by a group of Dunedin schoolchildren. Zentralbl Bakteriol 1990;274:100-8
19. Tagg JR. Significance of bacteriocin production by oral streptococci. In: Lutticken R, editor. Proceedings of the Xth Lancefield Symposium. Gustav Fischer Verlag; Stuttgart and New York; 1990
20. Dierksen KP, Tagg JR. The influence of indigenous bacteriocin-producing Streptococcus salivarius on the acquisition of Streptococcus pyogenes by primary school children in Dunedin. In: Martin DR, Tagg JR, editors. Streptococci and streptococcal diseases entering the new millennium. Securacopy; Auckland, New Zealand: 2000. p. 81-5
21. Di Pierro F, Donato G, Fomia F, et al. Preliminary pediatric clinical evaluation of the oral probiotic Streptococcus salivarius K12 in preventing recurrent pharyngitis and/or tonsillitis caused by Streptococcus pyogenes and recurrent acute otitis media. Int J Gen Med 2012;5:991-7